Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 7Withdrawn 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Pancreatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 15Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Hepatocellular 5Sarcoma 4Neoplasm Metastasis 4Bone Neoplasms 4Recurrence 3Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Histiocytoma, Malignant Fibrous 3Dermatofibrosarcoma 3Biliary Tract Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms, Unknown Primary 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Liposarcoma 2Leiomyosarcoma 2Hodgkin Disease 2Hemangiosarcoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Gemcitabine 2Taxes 1Polymerase Chain Reaction 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Gene Expression Profiling 1Docetaxel 1Cisplatin 1Capecitabine 1Bevacizumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Unknown Primary × Gemcitabine × Clear all
NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Rutgers, The State University of New Jersey

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Rigshospitalet, Denmark

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡